Skip to main
SRRK

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding is a biopharmaceutical company focused on developing innovative treatments for rare neuromuscular diseases. With promising clinical-stage pipeline candidates such as apitegromab and SRK-439, and a strong focus on early engagement with payers, the company is well positioned for future success. Additionally, with a diverse portfolio and a recent regulatory de-risking event, the company's strong financials and commitment to expanding the addressable patient population make it a compelling investment opportunity.

Bears say

Scholar Rock Holding is a biopharmaceutical company with a clinical-stage pipeline and early-stage programs focused on therapies for rare neuromuscular diseases. While the company has seen recent successes with the FDA's formal acceptance of their BLA resubmission and progress on their commercial launch plans, there are still risks to consider. Apitegromab and SRK-439 may not show sufficient efficacy and gene therapies could also limit the company's addressable market. Additionally, the company's valuation, based on a sum-of-parts analysis, may not be favorable for investors.

SRRK has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 13 analysts, SRRK has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.